Biodexa Pharmaceuticals (BDRX) Operating Expenses (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 12 years of Operating Expenses data on file, last reported at -$5.4 million in Q2 2025.

• For the quarter ending Q2 2025, Operating Expenses changed N/A year-over-year to -$5.4 million; the trailing twelve-month figure through Dec 2025 stood at -$10.8 million (up 2.61% YoY), and the FY2025 full-year result was -$11.6 million, up 2.09% from the prior year.
• Operating Expenses held at -$5.4 million in Q2 2025, from -$5.4 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$4.9 million in Q4 2021 to a low of -$5.7 million in Q2 2023.
• A 5-year average of -$5.3 million and a median of -$5.3 million in 2022 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses jumped 66.04% in 2021 and fell 4.04% in 2022, its largest moves.
• Tracing BDRX's Operating Expenses over 5 years: stood at -$4.9 million in 2021, then fell by 1.16% to -$5.0 million in 2022, then dropped by 13.7% to -$5.7 million in 2023, then rose by 4.64% to -$5.4 million in 2024, then advanced by 0.49% to -$5.4 million in 2025.
• Business Quant data shows BDRX's Operating Expenses at -$5.4 million in Q2 2025, -$5.4 million in Q4 2024, and -$5.7 million in Q2 2023.